David Wilkinson

Summary

Publications

  1. ncbi The pharmacology of donepezil: a new treatment of Alzheimer's disease
    D G Wilkinson
    University of Southampton, Thornhill Research Unit, Moorgreen Hospital, West End, Southampton, SO30 3JB, UK
    Expert Opin Pharmacother 1:121-35. 1999
  2. ncbi Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease
    D Wilkinson
    Old Age Psychiatry, Thornhill Research Unit, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 16:852-7. 2001
  3. ncbi Prophylactic therapy with lithium in elderly patients with unipolar major depression
    David Wilkinson
    MARC, Elderly Mental Health Directorate, Moorgreen Hospital, Southampton
    Int J Geriatr Psychiatry 17:619-22. 2002
  4. pmc Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 28:244-51. 2009
  5. doi A review of the effects of memantine on clinical progression in Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre MARC, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 27:769-76. 2012
  6. doi Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    J Alzheimers Dis 29:459-69. 2012
  7. ncbi Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 24:138-45. 2007
  8. doi The long-term efficacy and tolerability of donepezil in patients with vascular dementia
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 25:305-13. 2010
  9. doi Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    Clive Holmes
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK
    Lancet 372:216-23. 2008
  10. ncbi Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006

Detail Information

Publications17

  1. ncbi The pharmacology of donepezil: a new treatment of Alzheimer's disease
    D G Wilkinson
    University of Southampton, Thornhill Research Unit, Moorgreen Hospital, West End, Southampton, SO30 3JB, UK
    Expert Opin Pharmacother 1:121-35. 1999
    ..This drug evaluation will review the basic pharmacology of donepezil and place it in context with the trial data and the author's clinical experience with the drug...
  2. ncbi Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease
    D Wilkinson
    Old Age Psychiatry, Thornhill Research Unit, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 16:852-7. 2001
    ..To investigate whether Galantamine significantly improves the core symptoms of Alzheimer's disease (AD)...
  3. ncbi Prophylactic therapy with lithium in elderly patients with unipolar major depression
    David Wilkinson
    MARC, Elderly Mental Health Directorate, Moorgreen Hospital, Southampton
    Int J Geriatr Psychiatry 17:619-22. 2002
    ..To compare the relapse rate of elderly depressed patients taking low dose lithium as an additional therapy with antidepressant medication to those receiving antidepressant medication alone...
  4. pmc Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 28:244-51. 2009
    ..Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer's disease (AD)...
  5. doi A review of the effects of memantine on clinical progression in Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre MARC, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 27:769-76. 2012
    ..If given early, such a treatment would be expected to maximise any potential benefit. Memantine has shown clinical benefits in the key domains of AD, both as monotherapy and in combination with a cholinesterase inhibitor (ChEI)...
  6. doi Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    J Alzheimers Dis 29:459-69. 2012
    ..The biological relevance of cerebral atrophy was supported by a significant correlation between rate of atrophy and decline in cognitive and behavioral outcomes...
  7. ncbi Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 24:138-45. 2007
    ..Alzheimer's disease (AD) is a progressive neurodegenerative disorder and delaying disease worsening is a relevant treatment outcome...
  8. doi The long-term efficacy and tolerability of donepezil in patients with vascular dementia
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 25:305-13. 2010
    ..To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD)...
  9. doi Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    Clive Holmes
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK
    Lancet 372:216-23. 2008
    ..Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes...
  10. ncbi Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006
    ..Abeta immunotherapy can clear all Abeta species from the cortex. However, if it is to be used for treatment of established Alzheimer disease, then the residual tau pathology and cerebral amyloid angiopathy require further study...
  11. ncbi Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report
    James A R Nicoll
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    Nat Med 9:448-52. 2003
    ..The T-lymphocyte meningoencephalitis is likely to correspond to the side effect seen in some other patients who received AN-1792 (refs. 7-9)...
  12. ncbi The effect of link nurses on hospital readmission rates
    Paul Anthony Ashton
    Memory Assessment and Research Centre MARC, Moorgreen Hospital, Southampton
    Nurs Times 102:34-5. 2006
    ..This is a summary of the paper the full version can be accessed at nursingtimes.net...
  13. ncbi Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study
    Clive Holmes
    University of Southampton, School of Medicine, Community Clinical Sciences Research Division, Memory Assessment and Research Unit, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 17:305-8. 2002
    ..To determine whether aromatherapy with lavender oil is effective in the treatment of agitated behaviour in patients with severe dementia...
  14. ncbi Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study
    Clive Holmes
    Int J Geriatr Psychiatry 22:380-1. 2007
  15. ncbi Association between HIV-1 infection, the etiology of genital ulcer disease, and response to syndromic management
    Prashini Moodley
    Africa Centre for Health and Population Studies, Nelson R Mandela School of Medicine, University of Natal, Durban, South Africa
    Sex Transm Dis 30:241-5. 2003
    ..Reports on the effect of HIV-1 infection on healing rates of ulcers are conflicting...
  16. ncbi Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
    Alistair Burns
    University of Manchester, Manchester, UK
    J Psychopharmacol 20:732-55. 2006
    ..Patients, their carers, and clinicians deserve to be optimistic in a field which often attracts therapeutic nihilism...
  17. ncbi Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge
    Prashini Moodley
    Africa Centre for Population Studies and Reproductive Health, Faculty of Medicine, University of Natal, Durban, South Africa
    Sex Transm Dis 30:1-5. 2003
    ..Reports on microbiologic cure rates following syndromic management (SM) of women with nonulcerative sexually transmitted infections (STIs) are limited...